Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > RE"I Wonder

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Oct 23, 2022 11:08pm

158 Views

Post# 35042724

RE:RE"I Wonder

Unfounded insuinuation is your contunious claim that I am a paid pumper for which you have provided no proof to back up. And which I am sure you are smart enough to know the difference. So you either make the claim and don't know, so spread misinformation, or you do know are simply lying.

I think the latter.

<< Previous

Bullboard Posts

Next >>

Vizsla Silver's new resource estimate sends stock surging